KOSDAQElectronic Components238120

Aligned Genetics

₩2,780▲ 2.02%2026-11-18 close
Market Cap
₩39.5B
Turnover
₩38,555,145
Volume
10K
Shares out.
14.2M
PER
13.7×
PBR
1.0×
EPS
₩198
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue Growth Slows as Margins Narrow

Aligned Genetics' revenue rose for three straight years from 2023 to 2025, but growth slowed, its operating margin fell from 21.9% in 2023 to 15.3% in 2025, and it swung to a net loss attributable to controlling shareholders of KRW 922 million in the third quarter of 2026.

  1. 1

    Revenue grew from KRW 13.8 billion in 2022 to KRW 16 billion in 2025, but annual growth slowed from 10.6% in 2023 to 3.7% in 2024 and 1.5% in 2025.

  2. 2

    Operating profit peaked at KRW 3.34 billion in 2023 and then declined two years in a row, to KRW 2.78 billion in 2024 and KRW 2.44 billion in 2025.

  3. 3

    In the third quarter of 2026 the company posted a net loss attributable to controlling shareholders of KRW 922 million, and operating profit fell 48.4% year on year to KRW 281 million.

  4. 4

    The company points to European export expansion and point-of-care molecular diagnostics as growth drivers, and has agreed to acquire land and buildings in Gunpo for KRW 14 billion to relocate its headquarters and expand production.

  5. 5

    The debt ratio rose from 24.7% in 2024 to 55.5% in 2025, with total liabilities of KRW 20.6 billion at year-end 2025, making the capital structure a key item to check in the next annual report.

02

Business structure

Aligned Genetics was founded in October 2008 and develops and sells life science research and diagnostic instruments. Its main products are automated cell counting systems, tissue clearing and imaging systems, and digital cell imaging systems, designed by combining biotechnology, optics, electronics and software.

The flagship LUNA line of automated cell counters serves pharmaceutical and biotech companies and research institutes that need fast measurement of cell count and viability. The CELENA digital cell imaging system and the tissue clearing system broaden the portfolio toward cell observation and tissue analysis.

Once instruments are installed, demand for consumables such as counting slides follows, so instrument sales and recurring revenue arise together. The company says this model, which pairs research instrument sales with higher-margin consumables, supports earnings stability.

Segment revenue shares are not included in the disclosed figures. Based on 2019 data, export shares by product ranged from roughly 81% to 97%, though that year's mix may differ from today.

On the new-business side, media have reported that the company became the exclusive manufacturer and supplier of the CosmoSort single-cell analysis instrument, and in March 2026 it presented point-of-care molecular diagnostics as a new growth engine.

Competition overlaps with other research instrument makers in cell analysis and imaging, and the company has said that combining biotech, electronics, optics and software expertise is what secures market advantage.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩3.9B₩500M14.0%
2025Q4₩4.3B₩1.1B25.9%
2026Q1₩3.6B₩200M6.3%
2026Q2₩4.4B₩600M14.8%
2026Q3₩4B₩300M7.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩13.8B₩2.8B₩2.3B20.7%8.1%27.9%
2023₩15.2B₩3.3B₩3.2B21.9%10.3%30.7%
2024₩15.8B₩2.8B₩4.1B17.6%11.6%24.7%
2025₩16B₩2.4B₩2.9B15.3%7.8%55.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue rose from KRW 13.8 billion in 2022 to KRW 15.2 billion in 2023 (up 10.6% year on year), KRW 15.8 billion in 2024 (up 3.7%) and KRW 16 billion in 2025 (up 1.5%), and 2025 was the largest year of 2022 to 2025.

Growth slowed each year, and the company cited external factors behind the stagnation, including the US government shutdown, tariff concerns and cuts to government research budgets.

Operating profit went from KRW 2.85 billion in 2022 to KRW 3.34 billion in 2023 (up 17.1%), the peak, then fell 16.7% to KRW 2.78 billion in 2024 and 12.1% to KRW 2.44 billion in 2025, a decline in two consecutive years. The operating margin moved from 20.7% in 2022 to 21.9% in 2023, 17.6% in 2024 and 15.3% in 2025.

Operating profit fell while revenue rose, so the margin was squeezed, and the detailed cost and selling and administrative expense lines should be checked in the business report.

Net profit attributable to controlling shareholders was KRW 2.33 billion in 2022, KRW 3.24 billion in 2023 (up 38.7%) and KRW 4.13 billion in 2024 (up 27.6%), with 2024 the largest year, before falling 29.5% to KRW 2.91 billion in 2025.

Net profit including non-controlling interests was reported at the same amounts in each year. Operating cash flow rose from KRW 2.22 billion in 2022 to KRW 3.61 billion in 2025, above the KRW 2.91 billion of 2025 profit attributable to controlling shareholders.

Total equity at the end of 2025 was KRW 37.2 billion, all of it attributable to controlling shareholders, and total liabilities were KRW 20.6 billion. Quarterly results are volatile.

From KRW 3.89 billion in revenue, KRW 545 million in operating profit and KRW 933 million in controlling-shareholder net profit in the third quarter of 2025, the fourth quarter rose to KRW 4.28 billion in revenue (up 9.9% quarter on quarter), KRW 1.11 billion in operating profit (up 103.1%) and KRW 1.54 billion in controlling-shareholder net profit (up 65.2%).

The first quarter of 2026 fell back to KRW 3.64 billion in revenue, KRW 230 million in operating profit and KRW 418 million in controlling-shareholder net profit, and the second quarter recovered to KRW 4.35 billion, KRW 644 million and KRW 1.75 billion.

The third quarter of 2026 revenue of KRW 3.97 billion rose 2.1% year on year, but operating profit of KRW 281 million fell 48.4% year on year, and the company swung to a controlling-shareholder net loss of KRW 922 million.

Controlling-shareholder net profit for the last four quarters, from the fourth quarter of 2025 to the third quarter of 2026, totals KRW 2.79 billion.

05

Industry analysis

The market Aligned Genetics serves is linked to pharmaceutical and biotech R&D budgets and to laboratory equipment spending at universities and research institutes. A data provider compares Aligned Genetics with the KOSDAQ medical and precision instruments industry group.

Demand for research instruments is sensitive to the timing of research funding and to policy changes, so budget cycles matter more than the general manufacturing cycle.

The company attributed its revenue stagnation to the US government shutdown, tariff concerns and cuts to government research budgets, which shows exposure to external policy variables.

On the other hand, the company says cell counting and cell imaging are used in basic experimental workflows, so replacement and expansion demand is steady.

The diagnostics market is broadening toward molecular diagnostic instruments that deliver fast results at the point of care, as demand for early cancer detection and infectious disease response grows, and Aligned Genetics is trying to enter this flow with its POCT system.

In research instruments, performance matters alongside the consumables supply chain and the customer base, and media have reported that the company serves both pharmaceutical companies and university and research institutions.

Because export shares are high, with about 81% to 97% by product in 2019, competition and currency movements can affect profitability directly. The cycle position is hard to judge with certainty, so the direction of quarterly results in 2026 and the performance of the POCT business will serve as the reference points.

06

Outlook

In March 2026 the company said it would pursue a qualitative step-up through an active rollout of new products and stronger cost competitiveness. Point-of-care molecular diagnostics was presented as the new growth engine, with the aim of adding POCT to its life science analysis instruments to raise earnings stability.

Media have reported that the exclusive manufacturing and supply business for the CosmoSort single-cell analysis instrument is delivering to overseas pharmaceutical companies and hospital and university research institutions, which raises the possibility of a contribution from this new business.

Second-quarter 2026 revenue of KRW 4.35 billion and operating profit of KRW 644 million signal a quarterly recovery, but in the third quarter of 2026 operating profit of KRW 281 million and a controlling-shareholder net loss of KRW 922 million showed renewed volatility.

At its regular shareholders meeting in March 2026, the company approved partial amendments to its articles of incorporation, the re-election of an auditor, and a plan for holding and disposing of treasury shares.

The company disclosed that it will acquire land and buildings in Gunpo, Gyeonggi Province, worth KRW 14 billion, for relocating its headquarters and expanding production, a transaction equal to 31.62% of total assets.

How this facility investment affects production capacity and unit costs should be checked in the property, plant and equipment and liabilities items of the next annual report. The timing of new product launches for automated cell counters and of POCT commercialization can be confirmed through company disclosures.

The size of the POCT contribution to earnings is hard to gauge for now, because the business is not separately visible in the disclosed results.

07

Valuation

PER
13.7×
PBR
1.0×
ROE
7.6%
EPS
₩198
BPS
₩2,711
Dividend per share
₩0

A valuation view starts with earnings scale and the share price relative to net asset value. Controlling-shareholder net profit for the last four quarters totals KRW 2.79 billion, but the third quarter of 2026 was a net loss, so quarter-based multiples can swing sharply with earnings.

On an annual basis, controlling-shareholder net profit peaked at KRW 4.13 billion in 2024 and fell to KRW 2.91 billion in 2025, so whether earnings move back toward that peak is the central variable for reading the multiples.

With total equity of KRW 37.2 billion at the end of 2025 all attributable to controlling shareholders, the price-to-book ratio shows how large the premium over net assets is. The rise of the debt ratio to 55.5% in 2025 also has to be reflected when reading balance-sheet-based measures.

The dividend yield sits at a low level, so the stock's return depends more on price movement than on shareholder payouts. In industry comparison, the usual starting point is to measure whether the multiple sits at a premium or discount to the medical and precision instruments group on the KOSDAQ.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Recurring revenue from consumables

Once instruments are installed, demand for consumables such as counting slides follows, creating recurring revenue. The company says higher-margin consumables alongside instrument sales support earnings stability.

Operating cash flow also rose from KRW 2.22 billion in 2022 to KRW 3.61 billion in 2025, which points to sustained cash generation.

Overseas demand base and European expansion

Based on 2019 data, export shares by product were roughly 81% to 97%, indicating a broad overseas customer base. Financial data compiled by a market data provider showed cumulative revenue for the first nine months of 2025 rising 15.5% year on year, and the company cites European export expansion as a growth driver.

Revenue of KRW 4.28 billion in the fourth quarter of 2025 and KRW 4.35 billion in the second quarter of 2026 show quarterly sales reaching the mid-KRW 4 billion range.

New businesses and production capacity

In March 2026 the company presented point-of-care molecular diagnostics as a new growth engine, with the goal of launching new products and strengthening cost competitiveness.

Media have reported that the exclusive manufacturing and supply business for the CosmoSort single-cell analysis instrument is delivering to overseas pharmaceutical companies and research institutions.

The KRW 14 billion acquisition of land and buildings in Gunpo is intended for headquarters relocation and production expansion.

09

Bear factors

Steadily slowing revenue growth

Annual revenue growth slowed from 10.6% in 2023 to 3.7% in 2024 and 1.5% in 2025. Revenue of KRW 3.64 billion in the first quarter of 2026 fell 14.9% quarter on quarter.

The company cited external factors including government shutdowns, tariffs and research budget cuts, which shows that demand for research instruments is sensitive to policy.

Narrowing operating margin and quarterly volatility

The operating margin fell from 21.9% in 2023 to 15.3% in 2025. Operating profit of KRW 230 million in the first quarter of 2026 dropped 79.2% quarter on quarter.

In the third quarter of 2026, operating profit of KRW 281 million coexisted with a controlling-shareholder net loss of KRW 922 million, swinging the bottom line into a loss and signaling that earnings have not yet stabilized.

Rising debt and external dependence

The debt ratio rose from 24.7% in 2024 to 55.5% in 2025, with total liabilities of KRW 20.6 billion. Export shares were high in 2019, which exposes the company to currency and tariff variables.

The contribution of the POCT business to revenue is not visible in the disclosed results, so its actual effect is hard to gauge.

10

Risk factors

Research budgets and demand swings

Research instrument sales are sensitive to pharmaceutical and biotech R&D budgets and to laboratory budgets at universities and research institutes. US government shutdowns and cuts to government research funding have already been cited as reasons for revenue stagnation.

If budget execution slips, instrument orders can be pushed out by a quarter or more, adding to earnings volatility.

Tariffs, currency and export dependence

Export shares by product were about 81% to 97% in 2019, so overseas sales make up a large part of revenue. Tariff changes and currency movements can directly affect export profitability and won-denominated revenue. A slowdown in sales by overseas distribution partners would flow straight through to export results.

New-business commercialization and capex burden

The POCT diagnostics business depends on regulatory approval, quality control and commercialization timing. The KRW 14 billion Gunpo property acquisition and production expansion could add strain to the asset and liability structure. With the debt ratio at 55.5%, the pace of investment will shape financial stability.

11

What to watch next

  1. Late March 2027

    Annual report for 2026. Check the 2026 operating margin against 15.3% in 2025, the cost structure in the fourth quarter, and the reasons behind changes in total liabilities.

  2. Around late March 2027

    Results of the 2027 regular shareholders meeting. The 2026 meeting was disclosed on March 31 and approved articles amendments and a treasury share disposal plan, so changes in treasury share plans and agenda items should be checked.

  3. Mid-May 2027

    First-quarter 2027 results. Compare against KRW 3.64 billion in revenue, KRW 230 million in operating profit and KRW 418 million in controlling-shareholder net profit in the first quarter of 2026 to see whether quarterly profitability holds.

  4. First half of 2027

    Disclosures on the POCT product launch and the Gunpo production expansion. Check whether the new business begins contributing revenue and how quickly capital spending proceeds.

12

Overall view

Aligned Genetics' revenue rose from KRW 13.8 billion in 2022 to KRW 16 billion in 2025, but growth slowed from 10.6% to 1.5%, and operating profit declined two years in a row after its 2023 peak. The operating margin also fell from 21.9% in 2023 to 15.3% in 2025.

Controlling-shareholder net profit peaked at KRW 4.13 billion in 2024 and fell to KRW 2.91 billion in 2025, and in the third quarter of 2026 the company swung to a net loss of KRW 922 million.

On the other side, operating cash flow rose to KRW 3.61 billion in 2025, and the company describes its consumables-linked model and overseas demand base as strengths. Weak points are sensitivity to research budgets and external policy, the narrowing margin, and the rise of the debt ratio to 55.5%.

How the POCT business and the Gunpo production expansion show up in reported results will be the reference for reading the trend ahead. Controlling-shareholder net profit for the last four quarters totals KRW 2.79 billion. The next checkpoints are the 2026 annual report and first-quarter 2027 results.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 14 more articles and sources
  1. comp.fnguide.com
  2. asp01.fnguide.com
  3. apnews.kr
  4. kr.investing.com
  5. investing-for-everyone.com
  6. news.nate.com
  7. marketin.edaily.co.kr
  8. m.finance.daum.net
  9. eduinfom.com
  10. jobkorea.co.kr
  11. mt.co.kr
  12. thevc.kr
  13. kr.investing.com
  14. lge.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis